A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.

A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Budesonide
Crohn Disease
Double-Blind Method
Drug Administration Schedule
Female
Gastrointestinal Agents
Humans
Male
Middle Aged
Prednisolone
Quality of Life
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha

authors with profiles

Stephen B. Hanauer